Circulating microRNA profiles and the identification of miR-593 and miR-511 which directly target the PROP1 gene in children with combined pituitary hormone deficiency

Hu,Yanyan; Wang,Qian; Wang,Zengmin; Wang,Fengxue; Guo,Xiaobo; Li,Guimei

doi:10.3892/ijmm.2014.2016

Circulating microRNA profiles and the identification of miR-593 and miR-511 which directly target the PROP1 gene in children with combined pituitary hormone deficiency

Authors:
- Yanyan Hu
- Qian Wang
- Zengmin Wang
- Fengxue Wang
- Xiaobo Guo
- Guimei Li
View Affiliations

Affiliations: Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: November 28, 2014 https://doi.org/10.3892/ijmm.2014.2016
Pages: 358-366
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since the tissue of children with combined pituitary hormone deficiency (CPHD) is not readily accessible, a new focus in children with CPHD is the blood-based expression profiling of non-protein coding genes, such as microRNAs (miRNAs or miRs), which regulate gene expression by inhibiting the translation of mRNAs. In this study, to address this, we identified potential miRNA signatures for CPHD by comparing genome-wide miRNA expression profiles in the serum of children with CPHD vs. normal (healthy) controls. Human embryonic kidney 293T cells were transfected with miR-593 or miR-511 oligonucleotides. Potential target gene expression was validated by western blot analysis for proteins and by miR-593 or miR-511 reporter assay using PROP1 gene 3'-untranslated region (3'-UTR) reporter. The miR-593 and miR-511 levels in the serum of 103 children with CPHD were assessed using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) method. We found 23 upregulated and 19 downregulated miRNAs with abnormal expression in children with CPHD compared with the normal controls using miRNA microarray analysis and RT-qPCR. miR-593 and miR-511 targeted the 3'-UTR of the PROP1 gene and attenuated the expression of PROP1. The levels of miR-593 and miR-511 in the serum of children with CPHD were increased compared with those in the control subjects. According to Youden's index, the sensitivity was 82.54 and 84.86%, and the specificity was 98.15 and 91.36% for miR-593 and miR-511, respectively. The various levels of specific miRNAs, particularly miR-593 and miR-511 whose direct target is the PROP1 gene, may serve as a non-invasive diagnostic biomarkers for children with CPHD.

View Figures

View References

1	Kandemir N, Vurallı D, Taşkıran E, Gönç N, Özön A, Alikaşifoğlu A and Yılmaz E: Frequency of mutations in PROP-1 gene in Turkish children with combined pituitary hormone deficiency. Turk J Pediatr. 54:570–575. 2012.
2	Kelberman D, Turton JP, Woods KS, et al: Molecular analysis of novel PROP1 mutations associated with combined pituitary hormone deficiency (CPHD). Clin Endocrinol (Oxf). 70:96–103. 2009. View Article : Google Scholar
3	Reynaud R, Albarel F, Saveanu A, et al: Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms. Eur J Endocrinol. 164:457–465. 2011. View Article : Google Scholar : PubMed/NCBI
4	Tauber M, Chevrel J, Diene G, et al: Long-term evolution of endocrine disorders and effect of GH therapy in 35 patients with pituitary stalk interruption syndrome. Horm Res. 64:266–273. 2005. View Article : Google Scholar : PubMed/NCBI
5	Cruz JB, Nunes VS, Clara SA, Perone D, Kopp P and Nogueira CR: Molecular analysis of the PROP1 and HESX1 genes in patients with septo-optic dysplasia and/or pituitary hormone deficiency. Arq Bras Endocrinol Metabol. 54:482–487. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ward RD, Raetzman LT, Suh H, Stone BM, Nasonkin IO and Camper SA: Role of PROP1 in pituitary gland growth. Mol Endocrinol. 19:698–710. 2005. View Article : Google Scholar
7	Cogan JD, Wu W, Phillips JA III, et al: The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab. 83:3346–3349. 1998.PubMed/NCBI
8	Cohen LE, Wondisford FE, Salvatoni A, Maghnie M, Brucker-Davis F, Weintraub BD and Radovick S: A ‘hot spot’ in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates. J Clin Endocrinol Metab. 80:679–684. 1995.PubMed/NCBI
9	Wu W, Cogan JD, Pfaffle RW, et al: Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet. 18:147–149. 1998. View Article : Google Scholar : PubMed/NCBI
10	Arroyo A, Pernasetti F, Vasilyev VV, Amato P, Yen SS and Mellon PL: A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty. Clin Endocrinol (Oxf). 57:283–291. 2002. View Article : Google Scholar
11	Deladoëy J1, Flück C, Büyükgebiz A, et al: ‘Hot spot’ in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab. 84:1645–1650. 1999.
12	Parks JS, Brown MR, Hurley DL, Phelps CJ and Wajnrajch MP: Heritable disorders of pituitary development. J Clin Endocrinol Metab. 84:4362–4370. 1999.PubMed/NCBI
13	Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI
14	Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res. 106:1035–1039. 2010. View Article : Google Scholar : PubMed/NCBI
15	Vlassov VV, Laktionov PP and Rykova EY: Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med. 10:142–165. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cortez MA and Calin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 9:703–711. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hoekstra M, van der Lans CA, Halvorsen B, et al: The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun. 394:792–797. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW and Jeyaseelan K: Expression profile of MicroRNAs in young stroke patients. PLoS One. 4:e76892009. View Article : Google Scholar : PubMed/NCBI
19	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
20	Zampetaki A, Kiechl S, Drozdov I, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 107:810–817. 2010. View Article : Google Scholar : PubMed/NCBI
21	Guo X, Guo L, Ji J, et al: miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun. 398:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ratert N, Meyer HA, Jung M, et al: miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705. 2013. View Article : Google Scholar : PubMed/NCBI
23	Sethi S, Kong D, Land S, Dyson G, Sakr WA and Sarkar FH: Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am J Transl Res. 5:200–211. 2013.PubMed/NCBI
24	Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
25	Lau NC, Lim LP, Weinstein EG and Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 294:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
26	Lee RC and Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001. View Article : Google Scholar : PubMed/NCBI
27	Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H and Hu C: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 139:223–229. 2013. View Article : Google Scholar :
28	Wang K, Zhang S, Marzolf B, et al: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 106:4402–4407. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wang GK, Zhu JQ, Zhang JT, et al: Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 31:659–666. 2010. View Article : Google Scholar : PubMed/NCBI